Primary Recipient

EPIVAX, INC.

Amount

$215,016.00

Award Date

9/17/2009

Administering Agency

Health and Human Services, Department of / National Institutes of Health

CDFA Number

93.701

CDFA Program Title

Trans-NIH Recovery Act Research Support

Description

The goal of this new R21 proposal is to develop a pro-inflammatory and non-tolerogenic HIV vaccine delivery system based on the dendritic cell targeting anti-DEC-205 antibody. The success of anti-DEC-205 as a stimulator of strong inflammatory immune respo

Recipients Connected to Award

Recipient	Role	Amount
EPIVAX, INC.	Primary recipient	$171,442.00
SAINT LOUIS UNIVERSITY	Sub-recipient	$43,574.00